CL2017003245A1 - 1,4-substituted piperidine derivatives - Google Patents

1,4-substituted piperidine derivatives

Info

Publication number
CL2017003245A1
CL2017003245A1 CL2017003245A CL2017003245A CL2017003245A1 CL 2017003245 A1 CL2017003245 A1 CL 2017003245A1 CL 2017003245 A CL2017003245 A CL 2017003245A CL 2017003245 A CL2017003245 A CL 2017003245A CL 2017003245 A1 CL2017003245 A1 CL 2017003245A1
Authority
CL
Chile
Prior art keywords
substituted
compounds
substituted piperidine
piperidine derivatives
methods
Prior art date
Application number
CL2017003245A
Other languages
Spanish (es)
Inventor
Nadine C Becknell
Reddeppa Reddy Dandu
Bruce D Dorsey
Dimitar B Gotchev
Robert L Hudkins
Linda Weinberg
Craig A Zificsak
Allison L Zulli
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of CL2017003245A1 publication Critical patent/CL2017003245A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

<p>SE DESCRIBEN EN LA PRESENTE COMPUESTOS DE PIPERIDINA 1,4-SUSTITUIDOS DE ACUERDO CON LA FÓRMULA (I) QUE HAN MOSTRADO ACTIVIDAD COMO INHIBIDORES DE ÁCIDO GRASO SINTASA. TAMBIÉN SE DESCRIBEN EN LA PRESENTE COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN LOS COMPUESTOS DE PIPERIDINA 1,4-SUSTITUIDOS DESCRITOS, Y MÉTODOS PARA TRATAR ENFERMEDADES MEDIADAS POR ÁCIDO GRASO SINTASA AL ADMINISTRAR UNO O MÁS DE LOS COMPUESTOS O FORMULACIONES FARMACÉUTICAS DESCRITAS EN LA PRESENTE. TAMBIÉN SE DESCRIBEN EN LA PRESENTE MÉTODOS PARA SINTETIZAR LOS COMPUESTOS DESCRITOS, INCLUYENDO LOS COMPUESTOS DE 1,4-SUSTITUIDOS E INTERMEDIARIOS SINTÉTICOS ÚTILES EN ESAS SÍNTESIS.</p><p> ARE DESCRIBED IN THE PRESENT PIPERIDINE COMPOUNDS 1,4-SUBSTITUTED IN ACCORDANCE WITH FORMULA (I) THAT HAVE SHOWN ACTIVITY AS SYNTHEASE FATTY ACID INHIBITORS. ALSO DESCRIBED IN THE PRESENT PHARMACEUTICAL COMPOSITIONS CONTAINING THE 1,4-SUBSTITUTED PIPERIDINE COMPOUNDS DESCRIBED, AND METHODS TO TREAT DISEASES MEDIUM BY SYNTHETIC ACID WHEN ADMINISTERING ONE OR MORE THAN PERFORMANCE COMPUTERS. THEY ARE ALSO DESCRIBED IN THIS METHODS TO SYNTHEIZE THE DESCRIBED COMPOUNDS, INCLUDING THE 1,4-SUBSTITUTED AND SYNTHETIC INTERMEDIATE COMPOUNDS IN THOSE SYNTHESIS. </p>

CL2017003245A 2015-06-18 2017-12-18 1,4-substituted piperidine derivatives CL2017003245A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562181384P 2015-06-18 2015-06-18

Publications (1)

Publication Number Publication Date
CL2017003245A1 true CL2017003245A1 (en) 2018-06-08

Family

ID=56373111

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003245A CL2017003245A1 (en) 2015-06-18 2017-12-18 1,4-substituted piperidine derivatives

Country Status (18)

Country Link
US (5) US9902696B2 (en)
EP (1) EP3310441B1 (en)
JP (2) JP6999424B2 (en)
KR (1) KR20180026459A (en)
CN (1) CN107847765B (en)
AU (1) AU2016280255A1 (en)
BR (1) BR112017027339A2 (en)
CA (1) CA3014554A1 (en)
CL (1) CL2017003245A1 (en)
CO (1) CO2018000344A2 (en)
EA (1) EA201890086A1 (en)
ES (1) ES2821049T3 (en)
HK (2) HK1252793A1 (en)
IL (1) IL256324B (en)
MX (1) MX2017016669A (en)
PE (1) PE20180572A1 (en)
PH (1) PH12017502331A1 (en)
WO (1) WO2016205633A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2905751A1 (en) 2013-03-13 2014-10-09 Forma Therapeutics, Inc. Novel compounds and compositions for inhibition of fasn
CA3014432C (en) 2015-06-18 2024-05-07 Cephalon, Inc. Substituted 4-benzyl and 4-benzoyl piperidine derivatives
PE20180572A1 (en) 2015-06-18 2018-04-04 Cephalon Inc 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES
WO2019052932A1 (en) 2017-09-18 2019-03-21 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
EP3636637A1 (en) * 2018-10-10 2020-04-15 Forma Therapeutics, Inc. Inhibiting fatty acid synthase (fasn)
TWI767148B (en) 2018-10-10 2022-06-11 美商弗瑪治療公司 Inhibiting fatty acid synthase (fasn)
WO2020092395A1 (en) 2018-10-29 2020-05-07 Forma Therapeutics, Inc. SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1 H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE
CN114945559A (en) * 2020-01-08 2022-08-26 坎特罗治疗有限公司 Preparation method of triazole glycolate oxidase inhibitor
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
CR20230057A (en) 2020-07-02 2023-08-15 Incyte Corp Tricyclic urea compounds as jak2 v617f inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
CA3211748A1 (en) 2021-02-25 2022-09-01 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
EP4053112A1 (en) 2021-03-03 2022-09-07 Bayer AG Method for the preparation of substituted 4-oxo-tetrahydrofuran
EP4053113A1 (en) 2021-03-03 2022-09-07 Bayer AG Improved method for the preparation of alky-4-oxo-tetrahydrofuran-2,3-dicarboxylate
EP4387965A2 (en) 2021-08-18 2024-06-26 ChemoCentryx, Inc. Aryl sulfonyl compounds as ccr6 inhibitors
AU2022328699A1 (en) 2021-08-18 2024-03-07 Chemocentryx, Inc. Aryl sulfonyl (hydroxy) piperidines as ccr6 inhibitors
WO2023078252A1 (en) 2021-11-02 2023-05-11 Flare Therapeutics Inc. Pparg inverse agonists and uses thereof
AU2022407173A1 (en) * 2021-12-10 2024-06-27 Prothena Biosciences Limited Heterocyclic compounds as dyrk1a inhibitors
WO2023186692A1 (en) 2022-03-28 2023-10-05 Bayer Aktiengesellschaft Method for producing cis-4-aminotetrahydrofuran-2-carboxylic acid esters

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486525A (en) 1993-12-16 1996-01-23 Abbott Laboratories Platelet activating factor antagonists: imidazopyridine indoles
WO2000035886A2 (en) * 1998-12-18 2000-06-22 Axys Pharmaceuticals, Inc. (hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors
AU2001278945A1 (en) 2000-08-10 2002-02-25 Eli Lilly And Company 4-substituted d-glutamic acid derivatives for use as antibiotic
HU228316B1 (en) * 2001-12-13 2013-03-28 Daiichi Sankyo Company Pyrazolopyrimidinone derivatives having pde7-inhibitory activity
JP4887626B2 (en) 2002-09-17 2012-02-29 Ｊｎｃ株式会社 Silicon compounds
WO2005014543A1 (en) 2003-08-06 2005-02-17 Japan Tobacco Inc. Condensed ring compound and use thereof as hcv polymerase inhibitor
WO2005037198A2 (en) 2003-10-06 2005-04-28 Glaxo Group Limited Preparation of 1,7-disubstituted azabenzimidazoles as kinase inhibitors
EP1688420A4 (en) 2003-11-19 2008-10-22 Japan Tobacco Inc 5-5-membered fused heterocyclic compound and use thereof as hcv polymerase inhibitor
UA83416C2 (en) 2004-02-13 2008-07-10 Баниу Фармасьютикал Ко., Лтд. Fused ring 4-oxopyrimidine derivative
CN1922141A (en) 2004-02-23 2007-02-28 大日本住友制药株式会社 Novel heterocyclic compound
ATE507206T1 (en) 2004-06-30 2011-05-15 Janssen Pharmaceutica Nv ARYL-SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE ETHER AS ACTIVE INGREDIENTS AGAINST CANCER
MX2008008337A (en) 2005-12-21 2008-09-03 Schering Corp Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists.
US20090048276A1 (en) 2006-01-30 2009-02-19 Goulet Mark T Inhibitors of Fatty Acid Synthase (Fas)
US8263772B2 (en) 2006-06-08 2012-09-11 Eli Lilly And Company MCH receptor antagonists
US7625746B2 (en) 2006-07-24 2009-12-01 Nanosphere, Inc. Method of denaturing and fragmenting DNA or RNA using ultrasound
EP2069312B1 (en) 2006-07-25 2012-11-07 Cephalon, Inc. Pyridizinone derivatives
TW200831092A (en) 2006-12-21 2008-08-01 Astrazeneca Ab Therapeutic agents
CA2672172C (en) 2006-12-22 2016-05-03 Astex Therapeutics Limited Bicyclic heterocyclic compounds as fgfr inhibitors
MX2009008338A (en) 2007-02-05 2009-08-12 Xenon Pharmaceuticals Inc Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions.
JP2010526120A (en) 2007-05-09 2010-07-29 ノバルティス アーゲー Substituted imidazopyridazines as PI3K lipid kinase inhibitors
AR067326A1 (en) 2007-05-11 2009-10-07 Novartis Ag IMIDAZOPIRIDINES AND PIRROLO -PIRIMIDINES REPLACED AS INHIBITORS OF LIPIDO KINASE
US20110288052A1 (en) 2008-06-02 2011-11-24 Townsend Craig A Novel compounds, pharmaceutical compositions containing same, and methods of use for same
US20110136790A1 (en) 2008-07-23 2011-06-09 De Lera Ruiz Manuel Tricyclic Heterocyclic Derivatives and Methods of Use
WO2010048149A2 (en) * 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
JP5795304B2 (en) 2009-03-18 2015-10-14 レスバーロジックス コーポレイション New anti-inflammatory agent
CA2763485C (en) 2009-05-27 2018-05-15 Neil Almstead Methods for treating cancer and non-neoplastic conditions
WO2011048018A1 (en) 2009-10-19 2011-04-28 Boehringer Ingelheim International Gmbh Cyclopentanecarboxamide derivatives, medicaments containing such compounds and their use
US20120208827A1 (en) 2009-10-27 2012-08-16 Glaxosmithkline Llc Benzimidazoles as fatty acid synthase inhibitors
JP2013032290A (en) 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd Novel fused pyrimidine derivative
WO2011066211A1 (en) 2009-11-24 2011-06-03 Glaxosmithkline Llc Azabenzimidazoles as fatty acid synthase inhibitors
SI3124481T1 (en) 2010-02-16 2018-06-29 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
EP2536411A4 (en) * 2010-02-18 2013-08-07 Univ Princeton Inhibitors of long and very long chain fatty acid metabolism as broad spectrum anti-virals
CN102858175A (en) 2010-02-22 2013-01-02 葛兰素史密斯克莱有限责任公司 Triazolones as fatty acid synthase inhibitors
CA2798330A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
JP5794297B2 (en) 2010-05-07 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pyridazinone as a GPR119 agonist
JP2013166700A (en) 2010-06-02 2013-08-29 Dainippon Sumitomo Pharma Co Ltd Novel 4, 5-fused pyrimidine derivative
WO2012036233A1 (en) 2010-09-17 2012-03-22 塩野義製薬株式会社 Condensed heterocyclic derivative having melanine-concentrating hormone receptor antagonistic activity
JP2013542960A (en) 2010-11-08 2013-11-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド Fatty acid synthase inhibitor
CA2818050A1 (en) 2010-11-26 2012-05-31 Lupin Limited Bicyclic gpr119 modulators
US20130303551A1 (en) 2011-01-10 2013-11-14 Nicholas D. Adams Pyrimidinone derivatives as fatty acid synthase inhibitors
ES2883274T3 (en) 2011-03-08 2021-12-07 Sagimet Biosciences Inc Heterocyclic modulators of lipid synthesis
AR086042A1 (en) 2011-04-28 2013-11-13 Galapagos Nv USEFUL COMPOUND FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES AND PHARMACEUTICAL COMPOSITION
WO2012167423A1 (en) 2011-06-08 2012-12-13 Hutchison Medipharma Limited Substituted pyridopyrazines as novel syk inhibitors
WO2012175520A1 (en) 2011-06-20 2012-12-27 Novartis Ag Hydroxy substituted isoquinolinone derivatives
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
US9084794B2 (en) 2011-08-19 2015-07-21 Glaxosmithkline Intellectual Property (No. 2) Limited Fatty acid synthase inhibitors
WO2013028445A1 (en) 2011-08-19 2013-02-28 Glaxosmithkline Llc Fatty acid synthase inhibitors
WO2013052716A1 (en) 2011-10-07 2013-04-11 Glaxosmithkline Llc Fatty acid synthase inhibitors
WO2013053051A1 (en) 2011-10-12 2013-04-18 University Health Network Indazole compounds as kinase inhibitors and method of treating cancer with same
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US20130281399A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
CN104662018B (en) 2012-04-20 2017-10-24 阿迪维纳斯治疗有限公司 Substituted Heterobicyclic compounds, composition and its medical applications
KR101415174B1 (en) 2012-04-26 2014-07-04 (주) 메디프론디비티 Novel benzoxazol derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition for prevention or treatment of RAGE receptor related diseases containing the same as an active ingredient
TWI585088B (en) 2012-06-04 2017-06-01 第一三共股份有限公司 Imidazo[1,2-b]pyridazine analogues as kinase inhibitors
WO2014004863A2 (en) * 2012-06-27 2014-01-03 Alzheimer's Institute Of America, Inc. Compounds, compositions, and therapeutic uses thereof
BR112015000106B1 (en) 2012-07-03 2022-02-22 Sagimet Biosciences Inc Heterocyclic lipid synthesis modulators, pharmaceutical composition and use of said modulators
US9353107B2 (en) 2012-07-03 2016-05-31 Aurigene Discovery Technologies Limited 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives as kinase inhibitors
EP2888005B1 (en) 2012-08-22 2019-04-03 Merck Sharp & Dohme Corp. Novel azabenzimidazole hexahydrofuro[3,2-b]furan derivatives
CA2884355C (en) 2012-09-07 2022-05-17 Janssen Pharmaceutica Nv Imidazolin-5-one derivative useful as fasn inhobitors for the treatment of cancer
AR092211A1 (en) 2012-09-24 2015-04-08 Merck Patent Ges Mit Beschränkter Haftung HYDROPIRROLOPIRROL DERIVATIVES
WO2014053568A1 (en) 2012-10-02 2014-04-10 Sanofi Indolyldihydroimidazopyrimidinone derivatives, preparation thereof and therapeutic use thereof
US9732032B2 (en) 2012-11-16 2017-08-15 Merck Patent Gmbh 3-aminocyclopentane carboxamide derivatives
CA2905751A1 (en) 2013-03-13 2014-10-09 Forma Therapeutics, Inc. Novel compounds and compositions for inhibition of fasn
EP2970311A4 (en) * 2013-03-14 2016-11-23 Brigham & Womens Hospital Bmp inhibitors and methods of use thereof
UY35400A (en) 2013-03-15 2014-10-31 Novartis Ag COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITARY DISEASES
US9809552B2 (en) 2013-03-21 2017-11-07 Merck Patent Gmbh Piperazine derivatives as FASN inhibitors
KR101524208B1 (en) 2013-04-26 2015-05-29 한국화학연구원 Benzoin oxazole derivatives, preparation method thereof and pharmaceutical compositions that contain them
US9172428B2 (en) 2013-06-28 2015-10-27 Intel Corporation Determining the spectral energy content of a data bus
MX2016001134A (en) 2013-07-29 2016-04-29 Merck Patent Gmbh 1,3-disubstituted cyclopentane derivatives.
DE102013215035B3 (en) 2013-07-31 2014-11-06 Siemens Aktiengesellschaft Soft redundancy protocol
EP3077387B1 (en) 2013-12-03 2017-12-20 Janssen Pharmaceutica NV Benzamide derivative useful as fasn inhibitors for the treatment of cancer
US10513521B2 (en) 2014-07-15 2019-12-24 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting BMP
WO2016041201A1 (en) 2014-09-19 2016-03-24 上海创诺医药集团有限公司 Thienopyrimidine derivatives and preparation method therefor and medical application thereof
TW201629033A (en) 2014-10-08 2016-08-16 健生藥品公司 Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes
CA3014432C (en) 2015-06-18 2024-05-07 Cephalon, Inc. Substituted 4-benzyl and 4-benzoyl piperidine derivatives
PE20180572A1 (en) 2015-06-18 2018-04-04 Cephalon Inc 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES

Also Published As

Publication number Publication date
PE20180572A1 (en) 2018-04-04
IL256324B (en) 2020-06-30
US20160368874A1 (en) 2016-12-22
US10851057B2 (en) 2020-12-01
US20180179159A1 (en) 2018-06-28
EP3310441A1 (en) 2018-04-25
EA201890086A1 (en) 2018-06-29
JP7307144B2 (en) 2023-07-11
US10221135B2 (en) 2019-03-05
AU2016280255A1 (en) 2018-02-08
CA3014554A1 (en) 2016-12-22
US11702388B2 (en) 2023-07-18
HK1252793A1 (en) 2019-06-06
CN107847765B (en) 2021-05-04
US20190152913A1 (en) 2019-05-23
EP3310441B1 (en) 2020-07-29
WO2016205633A1 (en) 2016-12-22
US20230391723A1 (en) 2023-12-07
KR20180026459A (en) 2018-03-12
HK1253048A1 (en) 2019-06-06
MX2017016669A (en) 2018-04-13
CO2018000344A2 (en) 2018-04-10
ES2821049T3 (en) 2021-04-23
US9902696B2 (en) 2018-02-27
US20210230116A1 (en) 2021-07-29
JP2018517754A (en) 2018-07-05
IL256324A (en) 2018-02-28
JP2022046612A (en) 2022-03-23
CN107847765A (en) 2018-03-27
PH12017502331A1 (en) 2018-06-04
JP6999424B2 (en) 2022-01-18
BR112017027339A2 (en) 2018-09-04

Similar Documents

Publication Publication Date Title
CL2017003245A1 (en) 1,4-substituted piperidine derivatives
CL2017002650A1 (en) Novel compounds
CL2017001488A1 (en) Benzamides substituted with 1,3-thiazol-2-yl
BR112018005497A2 (en) heterocyclic compounds and their uses
BR112015021983A2 (en) heterocyclic compounds and their uses
CL2017001675A1 (en) Quinazoline derivatives used to treat HIV
BR112012030711A2 (en) purinone derivative
BR112015022191A2 (en) heteroaryl compounds, their use and composition comprising them
UY36285A (en) COMPOUNDS THAT INHIBIT THE MCL-1 PROTEIN
CO7160104A2 (en) Hepatitis C virus inhibitors
CR20140464A (en) HETEROCICLYL COMPOUNDS
BR112014017749A8 (en) 3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF
UY35377A (en) 1,3-OXAZIN-2-AMINA COMPOUNDS FUSED WITH PERFLUORATED CYCLOPROPYL AS BETA-SECRETASE INHIBITORS AND METHODS OF USE
PE20151423A1 (en) TETRAHYDROPYRANIL DERIVATIVES INHIBITORS OF HCV
MX350588B (en) Semifluorinated alkane compositions.
UY34701A (en) SOLID FORMS OF A THIOPHOSPHORAMIDATE NUCLEOTIDE PROFIT
CL2017000432A1 (en) Cathepsin c spirocyclic inhibitors
BR112014000792A2 (en) Piperidinyl Compounds for Use as Tanquirase Inhibitors
BR112017004741A2 (en) compounds and compositions as raf kinase inhibitors
DOP2016000253A (en) NEW COMPOUNDS
NI201600014A (en) COMPOUNDS AND COMPOSITIONS AS MEK INHIBITORS.
MX2021009806A (en) Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same.
BR112016011170A8 (en) derivatives of heteroaryl butanoic acid, their uses, combination and pharmaceutical composition
DOP2015000170A (en) CHEMICAL COMPOUNDS
BR112015018491A2 (en) c-19-modified triterpenoids with hiv maturation inhibitory activity